NCT04617535

Brief Summary

Compassionate Use requests will be considered for individuals who test positive for SARS-CoV-2 and where there is reasonable basis to believe that the patient is infected with a susceptible variant.

Trial Health

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 2, 2020

Completed
3 days until next milestone

First Posted

Study publicly available on registry

November 5, 2020

Completed
Last Updated

October 3, 2023

Status Verified

September 1, 2023

First QC Date

November 2, 2020

Last Update Submit

September 29, 2023

Conditions

COVID-19

Keywords

Post-exposure

Interventions

REGN10933+REGN10987 combination therapyDRUG

Administered intravenously (IV) single dose

Also known as: REGN-COV2, Casirivimab, Imdevimab, REGEN-COV™, Ronapreve™

Sponsors & Collaborators

Related Publications (1)

  • Kreuzberger N, Hirsch C, Chai KL, Tomlinson E, Khosravi Z, Popp M, Neidhardt M, Piechotta V, Salomon S, Valk SJ, Monsef I, Schmaderer C, Wood EM, So-Osman C, Roberts DJ, McQuilten Z, Estcourt LJ, Skoetz N. SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19. Cochrane Database Syst Rev. 2021 Sep 2;9(9):CD013825. doi: 10.1002/14651858.CD013825.pub2.

    PMID: 34473343DERIVED

MeSH Terms

Conditions

COVID-19

Interventions

casirivimab and imdevimab drug combinationcasirivimabimdevimab

Condition Hierarchy (Ancestors)

Pneumonia, ViralPneumoniaRespiratory Tract InfectionsInfectionsVirus DiseasesCoronavirus InfectionsCoronaviridae InfectionsNidovirales InfectionsRNA Virus InfectionsLung DiseasesRespiratory Tract Diseases

Study Design

Study Type
expanded access
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 2, 2020

First Posted

November 5, 2020

Last Updated

October 3, 2023

Record last verified: 2023-09